We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Novavax (NVAX - Free Report) shares soared 20.1% in the last trading session to close at $12.56. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.4% gain over the past four weeks.
Shares surged as renewed investor interest in vaccine stocks sparked a broad sector rally. The immediate trigger was reports of a pneumonia-related death and quarantines in Russia, which fueled speculation around infectious-disease risks. At the same time, encouraging late-stage results on Vaxcyte’s investigational pneumococcal conjugate vaccine (PCV) further boosted sentiment across the vaccine sector.
Novavax’s gains were also supported by an improving underlying story, including approvals for its updated COVID-19 vaccine across key markets and its partnership with Sanofi, which could earn royalties from vaccine sales without bearing the full commercial costs.
This vaccine maker is expected to post quarterly loss of $0.37 per share in its upcoming report, which represents a year-over-year change of +40.3%. Revenues are expected to be $42.96 million, down 39% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Novavax, the consensus EPS estimate for the quarter has been revised 152.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on NVAX going forward to see if this recent jump can turn into more strength down the road.
Novavax is part of the Zacks Medical - Biomedical and Genetics industry. Vertex Pharmaceuticals (VRTX - Free Report) , another stock in the same industry, closed the last trading session 0.2% lower at $503.5. VRTX has returned -7.6% in the past month.
For Vertex, the consensus EPS estimate for the upcoming report has changed -4.5% over the past month to $4.86. This represents a change of +1.3% from what the company reported a year ago. Vertex currently has a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
Novavax (NVAX - Free Report) shares soared 20.1% in the last trading session to close at $12.56. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.4% gain over the past four weeks.
Shares surged as renewed investor interest in vaccine stocks sparked a broad sector rally. The immediate trigger was reports of a pneumonia-related death and quarantines in Russia, which fueled speculation around infectious-disease risks. At the same time, encouraging late-stage results on Vaxcyte’s investigational pneumococcal conjugate vaccine (PCV) further boosted sentiment across the vaccine sector.
Novavax’s gains were also supported by an improving underlying story, including approvals for its updated COVID-19 vaccine across key markets and its partnership with Sanofi, which could earn royalties from vaccine sales without bearing the full commercial costs.
This vaccine maker is expected to post quarterly loss of $0.37 per share in its upcoming report, which represents a year-over-year change of +40.3%. Revenues are expected to be $42.96 million, down 39% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Novavax, the consensus EPS estimate for the quarter has been revised 152.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on NVAX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Novavax is part of the Zacks Medical - Biomedical and Genetics industry. Vertex Pharmaceuticals (VRTX - Free Report) , another stock in the same industry, closed the last trading session 0.2% lower at $503.5. VRTX has returned -7.6% in the past month.
For Vertex, the consensus EPS estimate for the upcoming report has changed -4.5% over the past month to $4.86. This represents a change of +1.3% from what the company reported a year ago. Vertex currently has a Zacks Rank of #3 (Hold).